Scholarlink

<p>Eosinophilic gastrointestinal disorders (EGIDs) are treated with corticosteroids and food allergen elimination. However, treatment for refractory cases is not standardized. We demonstrate the efficacy of vedolizumab, an anti-α4β7 integrin agent, in 2 children with duodenal ulcers developed by non-eosinophilic esophagitis EGIDs. In both, vedolizumab was used continuously without side effects, and long-term remission has been durable. Duodenal ulcers associated with EGIDs are increasing. Vedolizumab has potential as a treatment for even upper gastrointestinal lesions in refractory EGIDs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Achievement of duodenal ulcer remission by vedolizumab in children with eosinophilic gastroenteritis

  • 期刊论文

  • 发表日期：

    2025年1月20日

查看全文
  • Riki Taniguchi,
  • Ryusuke Nambu,
  • Kayoko Ichimura,
  • Masashi Yoshida,
  • Tomoko Hara,
  • Itaru Iwama

摘要

Eosinophilic gastrointestinal disorders (EGIDs) are treated with corticosteroids and food allergen elimination. However, treatment for refractory cases is not standardized. We demonstrate the efficacy of vedolizumab, an anti-α4β7 integrin agent, in 2 children with duodenal ulcers developed by non-eosinophilic esophagitis EGIDs. In both, vedolizumab was used continuously without side effects, and long-term remission has been durable. Duodenal ulcers associated with EGIDs are increasing. Vedolizumab has potential as a treatment for even upper gastrointestinal lesions in refractory EGIDs.